Amgen
AMGN
$363.62
-1.19%
Amgen is a global biotechnology leader specializing in human therapeutics, with a portfolio spanning oncology, inflammation, bone health, and rare diseases. As one of the world's largest independent biotech firms, it distinguishes itself through a deep pipeline of innovative drugs and a growing biosimilar business. The current investor narrative centers on the integration of the Horizon Therapeutics acquisition, which added rare-disease assets like Tepezza, and the impact of new drug launches such as Lumakras and Tezspire, while facing headwinds from biosimilar competition and regulatory scrutiny on drugs like Tavneos.…
AMGN
Amgen
$363.62
Related headlines
Investment Opinion: Should I buy AMGN Today?
Rating: Buy. Amgen offers a compelling risk/reward with a forward P/E of 15.95x, a PEG ratio of 0.26x, and a consensus analyst target implying 16.9% upside. The thesis is that new product growth (Tezspire, Tepezza, Evenity) and Horizon synergies will drive earnings growth, while the low beta and 2.9% dividend yield provide downside protection.
Supporting evidence: (1) Forward P/E of 15.95x is below the industry average of ~18x and the stock's own trailing P/E of 22.84x. (2) Revenue grew 8.91% YoY in Q4 2025, with strong contributions from newer drugs. (3) Gross margin of 81.91% is well above the industry average of ~60%, reflecting pricing power. (4) Free cash flow TTM of $8.1B covers the dividend and capex, with a payout ratio of 66.5%. The implied analyst target of ~$437.60 offers 16.9% upside from the current price.
Risks & Conditions: The biggest risks are high debt (D/E 6.31x), Tavneos regulatory issues, and net margin compression. This Buy rating would downgrade to Hold if net margin fails to recover above 20% in the next two quarters, or if Tavneos sales are suspended. It would upgrade to Strong Buy if the debt-to-equity ratio falls below 4x or if new drug approvals accelerate. Overall, Amgen appears fairly valued relative to its growth prospects, with the forward P/E discounting a reasonable earnings recovery.
Sign up to view all
AMGN 12-Month Price Forecast
Amgen's outlook is cautiously bullish, supported by strong new product momentum and an attractive forward valuation. The base case of steady growth and margin recovery is most probable (50%), with the stock targeting $437.60. However, the high debt load and Tavneos regulatory overhang introduce significant uncertainty, limiting confidence to medium. If the company can demonstrate margin improvement and resolve Tavneos issues, the bull case (25% probability) could drive the stock above $400. Conversely, a bear case (25% probability) could see the stock fall toward $270 if risks materialize. The key factor to watch is net margin trajectory in the next two quarters.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $472.71 and implied upside of +30.0% versus the current price.
Average Target
$472.71
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$291 - $473
Analyst target range
Amgen is covered by 13 analysts, with a consensus leaning bullish. The average target price is not explicitly provided, but based on the estimated EPS of $27.44 for the next fiscal year and a forward P/E of 15.95x, the implied target is approximately $437.60, representing 16.9% upside from the current price of $374.15. The estimated EPS range is $26.49 to $28.78, and the revenue range is $41.50B to $44.24B, indicating moderate dispersion. Recent ratings include upgrades from Piper Sandler (Overweight) and Argus (Buy), while Freedom Broker downgraded to Hold. The consensus recommendation is likely a Buy, given the majority of ratings are Overweight or Buy. The high target of $28.78 EPS implies a price of ~$459 (using 15.95x forward P/E), suggesting 22.7% upside, while the low target of $26.49 EPS implies ~$422, or 12.8% upside. The relatively tight spread in EPS estimates (8.6% range) suggests analysts have moderate conviction in the near-term outlook, though the wide range in revenue estimates (6.6% spread) reflects uncertainty around new product uptake and biosimilar competition.
Bulls vs Bears: AMGN Investment Factors
Amgen presents a mixed investment case with strong growth from new products and attractive forward valuation, but faces significant risks from high debt, regulatory issues, and margin compression. The bull case is supported by a low PEG ratio (0.26x), robust free cash flow ($8.1B), and a consensus analyst target implying ~17% upside. However, the bear case highlights a debt-to-equity ratio of 6.31x, net margin volatility, and Tavneos safety concerns that could derail the rare-disease strategy. The single most important tension is whether the company can successfully integrate Horizon and grow new drugs fast enough to offset biosimilar headwinds and deleverage its balance sheet. Currently, the bull case has slightly stronger evidence given the valuation support and pipeline momentum, but the high debt and regulatory risks warrant caution.
Bullish
- Strong Revenue Growth from New Products: Q4 2025 revenue grew 8.91% YoY to $9.896B, driven by Tezspire ($474M), Tepezza ($457M), and Evenity ($599M). This diversification reduces reliance on legacy drugs and supports a higher growth trajectory.
- Attractive Forward Valuation: Forward P/E of 15.95x is below the industry average of ~18x and the stock's own trailing P/E of 22.84x, implying expected earnings growth. The PEG ratio of 0.26x suggests the stock is undervalued relative to its growth rate.
- High Gross Margins and Strong Cash Flow: Gross margin of 81.91% in Q4 2025 reflects the high-margin nature of biologics. Free cash flow TTM of $8.1B provides ample coverage for dividends ($1.283B paid in Q4) and capex ($642M), supporting a 2.9% dividend yield.
- Low Beta Provides Downside Protection: With a beta of 0.403, Amgen is significantly less volatile than the market. This makes it a defensive holding that can preserve capital during market downturns, appealing to risk-averse investors.
Bearish
- Elevated Debt from Horizon Acquisition: Debt-to-equity ratio of 6.31x is extremely high, reflecting the $28B Horizon acquisition. Interest expense of $653M in Q4 2025 weighs on net income, which dropped to $1.333B from $3.216B in Q3 due to higher operating costs.
- Regulatory and Safety Risks for Tavneos: The FDA warned of fatal liver risks linked to Tavneos, and Amgen's Japanese partner urged caution on its use. This could lead to sales restrictions or withdrawal, impacting the rare-disease portfolio and creating reputational damage.
- Biosimilar Competition Pressuring Legacy Drugs: Key legacy drugs like Enbrel ($532M in Q4) face biosimilar competition, which could erode market share and pricing power. This headwind may offset growth from newer products and compress margins over time.
- Net Margin Compression Due to Acquisition Costs: Net margin fell to 13.47% in Q4 2025 from 33.65% in Q3, driven by higher R&D ($2.151B) and SG&A costs. Integration expenses from Horizon and increased spending may continue to pressure profitability in the near term.
AMGN Technical Analysis
Amgen's stock is in a sustained uptrend, with a 1-year price change of +26.04%, significantly outperforming the S&P 500's +19.1%. The current price of $374.15 sits at 95.6% of its 52-week range ($269.77–$391.29), indicating the stock is near its highs and reflecting strong momentum, though it may be approaching overbought territory. Over the past 1 month, the stock surged 13.98%, while the 3-month change is +7.53%, showing accelerating short-term momentum that aligns with the longer-term uptrend. The 1-month relative strength versus SPY is +15.23%, confirming recent outperformance. The 52-week high of $391.29 acts as key resistance; a breakout above this level could signal further upside toward $400+. Support lies at the 52-week low of $269.77, but more immediate support is around $340 (recent consolidation area). With a beta of 0.403, Amgen is significantly less volatile than the market, making it a lower-risk holding that may underperform in strong bull markets but offers downside protection.
Beta
0.40
0.40x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$270-$391
Price range past year
Annual Return
+22.6%
Cumulative gain past year
| Period | AMGN Return | S&P 500 |
|---|---|---|
| 1m | +5.5% | +2.0% |
| 3m | +3.6% | +10.6% |
| 6m | +11.5% | +8.3% |
| 1y | +22.6% | +20.4% |
| ytd | +11.0% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMGN Fundamental Analysis
Revenue grew 8.91% year-over-year in Q4 2025 to $9.896 billion, driven by strong performance from newer products like Tezspire ($474M), Tepezza ($457M), and Evenity ($599M), while legacy drugs like Enbrel ($532M) remain stable. The trailing twelve-month revenue run rate is approximately $36.7 billion, with consistent sequential growth from $8.149B in Q1 2025 to $9.896B in Q4 2025. Net income in Q4 2025 was $1.333 billion, with a net margin of 13.47%, down from 33.65% in Q3 2025 due to higher operating expenses and acquisition-related costs. Gross margin remains strong at 81.91% in Q4 2025, reflecting the high-margin nature of biologics, though operating margin compressed to 39.83% from 61.87% in Q3 due to increased R&D spending ($2.151B) and SG&A costs. The company is profitable with a trailing P/E of 22.84x and an ROE of 89.06%, indicating efficient use of equity, though the high debt-to-equity ratio of 6.31x signals elevated leverage from the Horizon acquisition. Free cash flow for the trailing twelve months is $8.1 billion, providing ample coverage for dividends ($1.283B paid in Q4) and capex ($642M), with a current ratio of 1.14x suggesting adequate liquidity.
Quarterly Revenue
$9.9B
2025-12
Revenue YoY Growth
+8.91%
YoY Comparison
Gross Margin
81.91%
Latest Quarter
Free Cash Flow
$8.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMGN Overvalued?
Since net income is positive ($1.333B in Q4 2025), the primary valuation metric is the P/E ratio. The trailing P/E is 22.84x, while the forward P/E is 15.95x, implying the market expects significant earnings growth in the coming year. The gap between trailing and forward P/E suggests analysts anticipate a sharp earnings recovery, likely driven by cost synergies from Horizon and new product uptake. Compared to the industry average P/E of approximately 18x (Drug Manufacturers - General), Amgen's trailing P/E of 22.84x represents a 27% premium, which may be justified by its superior gross margin (70.8% vs. industry ~60%) and robust pipeline. Historically, Amgen's trailing P/E has ranged from 11x to 56x over the past five years; the current 22.84x is near the middle of that range, suggesting the stock is neither excessively cheap nor expensive relative to its own history. The PEG ratio of 0.26x indicates the stock is undervalued relative to its expected earnings growth rate, supporting a bullish valuation case.
PE
22.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -336x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Amgen's debt-to-equity ratio of 6.31x is among the highest in the biotech sector, a direct result of the $28B Horizon acquisition. Interest expense of $653M in Q4 2025 consumes a significant portion of operating income, and net income dropped to $1.333B from $3.216B in Q3 due to higher operating expenses. The company's net margin of 13.47% in Q4 is well below the TTM average of ~21%, indicating that integration costs and increased R&D spending ($2.151B) are pressuring profitability. Revenue concentration in newer products like Tezspire and Tepezza is growing, but these are still small relative to total revenue, leaving the company exposed if any fail to meet expectations.
Market & Competitive Risks: Amgen trades at a trailing P/E of 22.84x, a 27% premium to the industry average of ~18x, which could compress if growth disappoints. Biosimilar competition threatens legacy drugs like Enbrel ($532M in Q4), and the Tavneos safety warning (FDA fatal liver risk) could lead to sales restrictions. The stock's low beta of 0.403 provides downside protection but may cause it to underperform in strong bull markets. Recent news about potential 100% drug tariffs could impact Amgen if it hasn't secured pricing deals, though the company's U.S. manufacturing base may mitigate this risk.
Worst-Case Scenario: A perfect storm of Tavneos withdrawal, biosimilar erosion of Enbrel, and failure to achieve Horizon synergies could cause earnings to miss estimates. In this scenario, the stock could fall to its 52-week low of $269.77, representing a -27.9% decline from the current price of $374.15. The historical max drawdown of -16.57% provides a less severe but still significant downside reference. If the FDA restricts Tavneos and debt concerns mount, the stock could underperform for an extended period.
FAQ
The primary risks are financial, regulatory, and competitive. Financially, the debt-to-equity ratio of 6.31x is very high, and interest expense of $653M per quarter pressures net income. Regulatory risk centers on Tavneos, which received an FDA warning for fatal liver injuries; a withdrawal could hurt the rare-disease portfolio. Competitive risk comes from biosimilars targeting legacy drugs like Enbrel ($532M in Q4), which could erode revenue. Additionally, net margin compression to 13.47% in Q4 2025 from 33.65% in Q3 highlights earnings volatility. The most severe risk is a combination of these factors leading to a -27.9% decline to the 52-week low of $269.77.
The 12-month forecast is cautiously bullish, with a base case (50% probability) targeting $350-$438, centered on the analyst average of $437.60. The bull case (25% probability) sees the stock reaching $400-$459, driven by strong new product sales and margin recovery. The bear case (25% probability) could see the stock fall to $270-$350 if Tavneos issues escalate or debt concerns mount. The most likely scenario is steady growth with gradual margin improvement, supported by a forward P/E of 15.95x and estimated EPS of $27.44. Key catalysts include the next earnings report and FDA decisions on Tavneos.
Amgen appears undervalued based on forward earnings and growth prospects. The forward P/E of 15.95x is below the industry average of ~18x and the stock's own trailing P/E of 22.84x, implying the market expects significant earnings growth. The PEG ratio of 0.26x is well below 1.0, indicating the stock is cheap relative to its growth rate. Historically, the trailing P/E has ranged from 11x to 56x over five years; the current 22.84x is near the middle, suggesting it is not excessively priced. Compared to peers, Amgen's higher gross margin (81.91% vs. industry ~60%) justifies a slight premium, but the forward P/E still offers a discount. The market appears to be pricing in a cautious outlook due to debt and regulatory risks, creating a potential value opportunity.
Amgen is a good buy for investors seeking a defensive growth stock with a reasonable valuation. The forward P/E of 15.95x is below the industry average of 18x, and the PEG ratio of 0.26x suggests the stock is undervalued relative to its expected earnings growth. Analyst consensus is bullish, with an implied target of ~$437.60, offering 16.9% upside. However, the high debt-to-equity ratio of 6.31x and regulatory risks around Tavneos are significant concerns. For risk-averse investors with a 12-month horizon, the stock offers a favorable risk/reward, but those with lower tolerance for debt should wait for balance sheet improvement.
Amgen is better suited for long-term investment due to its low beta (0.403), stable dividend yield (2.9%), and GARP characteristics. The company's strong free cash flow ($8.1B TTM) and high gross margins provide a foundation for sustained growth and dividend increases. Short-term traders may find the stock less exciting given its low volatility, but the recent 13.98% one-month surge suggests momentum could continue. However, the high debt and regulatory risks make it less suitable for short-term speculation. A minimum holding period of 2-3 years is recommended to allow Horizon synergies to materialize and debt to decline, potentially unlocking value as the forward P/E re-rates toward the industry average.